Keith A. Johnson1, Reisa A. Sperling1, Christopher M. Gidicsin2, Jeremy S. Carmasin1, Jacqueline E. Maye2, Ralph E. Coleman3, Eric M. Reiman4, Marwan N. Sabbagh5, Carl H. Sadowsky6, Adam S. Fleisher4,7, P. Murali Doraiswamy3, Alan P. Carpenter8, Christopher M. Clark8, Abhinay D. Joshi8, Ming Lu8, Michel Grundman7,9, Mark A. Mintun8, Michel J. Pontecorvo8, Daniel M. Skovronsky8
1Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA
2Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
3Duke University Medical Center, Durham, NC, USA
4Banner Alzheimer's Institute, Phoenix, AZ, USA
5Banner Sun Health Research Institute, Sun City, AZ, USA
6Nova SE University, Ft. Lauderdale, FL, USA
7University of California San Diego, CA, USA
8Avid Radiopharmaceuticals, Philadelphia, PA, USA
9Global R&D Partners, San Diego, CA, USA
Tóm tắt
ObjectiveTo evaluate the performance characteristics of florbetapir F18 positron emission tomography (PET) in patients with Alzheimer's disease (AD), mild cognitive impairment (MCI), and healthy control subjects (HCs).MethodsFlorbetapir PET was acquired in 184 subjects (45 AD patients, 60 MCI patients, and 79 HCs) within a multicenter phase 2 study. Amyloid burden was assessed visually and quantitatively, and was classified as positive or negative.ResultsFlorbetapir PET was rated visually amyloid positive in 76% of AD patients, 38% of MCI patients, and 14% of HCs. Eighty‐four percent of AD patients, 45% of MCI patients, and 23% of HCs were classified as amyloid positive using a quantitative threshold. Amyloid positivity and mean cortical amyloid burden were associated with age and apolipoprotein E ε4 carrier status.ConclusionsThe data are consistent with expected rates of amyloid positivity among individuals with clinical diagnoses of AD and MCI, and indicate the potential value of florbetapir F18 PET as an adjunct to clinical diagnosis.
